Page last updated: 2024-11-06

fagaronine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Fagaronine is an alkaloid found in plants of the Rutaceae family, particularly in the genus Fagara. It has been shown to exhibit a range of biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. Research on fagaronine has been driven by its potential therapeutic applications, particularly in the treatment of inflammatory diseases and infections. The compound has shown promising activity against various cancer cell lines, prompting further investigation into its potential as an anticancer agent. Its unique chemical structure and biological activity have made it a subject of ongoing research, focusing on its synthesis, mechanism of action, and potential applications in medicine.'

fagaronine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID40305
CHEMBL ID121087
CHEBI ID28954
SCHEMBL ID424549
MeSH IDM0042531

Synonyms (22)

Synonym
2-hydroxy-3,8,9-trimethoxy-5-methylbenzo[c]phenanthridinium
CHEBI:28954 ,
brn 1554609
benzo(c)phenanthridinium, 2-hydroxy-3,8,9-trimethoxy-5-methyl-
benzo(c)phenanthridinium, 2-hydroxy-5-methyl-3,8,9-trimethoxy-
NEURO_000091
{benzo[c]phenanthridinium,} 2-hydroxy-3,8,9-trimethoxy-5-methyl-, chloride (mf1)
3,8,9-trimethoxy-5-methyl-5lambda~5~-benzo[c]phenanthridin-2-ol
3,8,9-trimethoxy-5-methyl-benzo[c]phenanthridin-5-ium-2-ol
fagaronine
52259-65-1
C09438
NCI60_001154
3,8,9-trimethoxy-5-methylbenzo[c]phenanthridin-5-ium-2-ol
CHEMBL121087
unii-59hne8rjs6
59hne8rjs6 ,
SCHEMBL424549
DTXSID30200298
Q17042674
2-hydroxy-3,8,9-trimethoxy-5-methylbenzo[c]phenanthridin-5-ium
2-hydroxy-3,8,9-trimethoxy-5-methylbenzo(c)phenanthridinium

Research Excerpts

Overview

Fagaronine (Fine) is a novel antileukemic drug extracted from Fagara xanthoxyloides Lam.

ExcerptReferenceRelevance
"Fagaronine (Fine) is a novel antileukemic drug extracted from Fagara xanthoxyloides Lam. "( Effect of fagaronine on cell cycle progression of human erythroleukemia K562 cells.
Carpentier, Y; Comoë, L; Desoize, B; Jardillier, JC, 1988
)
2.12

Toxicity

ExcerptReferenceRelevance
" Both compounds have toxic effects but no statistically significant increase in the frequency of spots was detected with the analogue of nitidine chloride."( Evaluation of genotoxicity of the indenoisoquinoline analogues of fagaronine and nitidine in Drosophila melanogaster.
Narváez, Z; Pérez-Chiesa, Y, 1993
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzophenanthridine alkaloidA specific group of isoquinoline alkaloids that occur only in higher plants and are constituents mainly of the Papaveraceae family.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (32.43)18.7374
1990's11 (29.73)18.2507
2000's11 (29.73)29.6817
2010's3 (8.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]